相关实验视频
Updated: Jul 24, 2025

00:07
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.4K
通过诱导EVA1A表达,PIWIL1促进乳头甲状腺癌的恶性进展
Lianyong Liu1, Fengying Wu2, Xiaoying Zhang3
1Department of Endocrinology and Metabolism, Punan Hospital, Pudong New Area, Shanghai 200125, China.
Current cancer drug targets
|July 5, 2023
概括
P元素诱导的小丸带1 (PIWIL1) 通过增强细胞生长和侵入,同时抑制细胞亡,驱动乳头甲状腺癌 (PTC) 的进展,这表明PIWIL1是治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 乳头甲状腺癌 (PTC) 是最常见的甲状腺恶性瘤.
- 在各种癌症中观察到P元素诱导的小丸带1 (PIWIL1) 的宫外表达.
- PIWIL1在PTC进展中的作用仍未得到研究.
研究的目的:
- 为了研究PIWIL1在乳头甲状腺癌中的作用和机制.
- 评估PIWIL1对PTC细胞增殖,细胞亡和侵入的影响.
- 在PTC中探索PIWIL1和Eva-1同源A (EVA1A) 之间的关系.
主要方法:
- 定量PCR (qPCR) 和西部Blot (WB) 用于测量PIWIL1和EVA1A的表达.
- 细胞活力测试用于评估增殖.
- 流细胞测量用于亡分析.
- 穿孔入侵测定和*in vivo*异种移植模型,以评估入侵和瘤生长.
主要成果:
- 在PTC组织中,PIWIL1的表达很高.
- PIWIL1促进PTC细胞的增殖,细胞周期的进展和入侵.
- 在PTC细胞中,PIWIL1抑制了细胞亡.
- 通过调节EVA1A的表达,PIWIL1加速了异种移植中的瘤生长.
结论:
- 通过EVA1A信号,PIWIL1有助于PTC进展.
- 皮维尔1代表了皮皮类甲状腺癌的潜在治疗标.
- 这项研究为开发新型PTC治疗提供了对PIWIL1功能的见解.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Induced Pluripotent Stem Cells
4.2K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K

